Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World, Retrospective Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer, With a Focus on Patients 65 Years and Older, and Patients Who Self-identify as African American

NCT07760714 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07760714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07760714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World, Retrospective Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer, With a Focus on Patients 65 Years and Older, and Patients Who Self-identify as African American
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
February 26, 2025
Completion date
August 29, 2025
Enrollment
945 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer